News

Advanced imaging and computer technologies aimed at providing for reliable prognosis leading to more personalized treatment.

The regulatory authorities in the Netherlands have approved the clinical trial application (CTA) to initiate a phase 1 study of the HuCAL-derived antibody MOR103.

Under the terms of the agreement, deCODE biostructures will conduct gene to structure research on multiple proprietary targets.

New agreement provides for development and promotion of OraQuick® HCV test outside the United States.

UCB has licensed BioBook to be deployed across multiple European sites for DMPK (Drug Metabolism and Pharmacokinetics) and pharmacology.

XmAb2513 is engineered to contain an XmAb™ Fc domain using Xencor’s Protein Design Automation® platform technology to greatly increase its cytotoxic potency.

The research collaboration is focused to discover and develop novel small molecule inhibitors of hepatitis C virus (HCV).

Company to expand its manufacturing operations to meet the demand for carbon nanotubes used by both its transparent electrode business and the market in general.

The Phase 1 trial is an open label, dose-escalation study assessing the pharmacokinetics and pharmacodynamics of SPI-1620 in patients with recurrent or progressive carcinoma.

The Company says that the new additions expand researchers’ ability to customize their sequencing projects to achieve scientifically meaningful results.